GlassScriptPhysician profile
Ansa Anderson
NPI 1376073015
$3,877.32
in general payments reported to CMS, 2019-2025
28 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $76.72 · 2021: $625 · 2022: $1,081 · 2023: $1,340 · 2024: $427 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,022.89 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $406.98 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $361.99 | 2021-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $317.01 | 2021-2025 | Trintellix |
| Lilly USA, LLC | $285.73 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $230.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $211.44 | 2020-2023 | Breztri, Farxiga |
| Optinose US, INC. | $118.72 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $115.73 | 2023-2024 | |
| Amgen INC. | $113.03 | 2020-2023 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $107.13 | 2022-2023 | |
| Axsome Therapeutics, INC. | $104.17 | 2023-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $66.36 | 2022 | |
| Esperion Therapeutics, INC. | $60.99 | 2020-2021 | |
| Abbott Laboratories | $60.21 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $39.15 | 2023 | Veozah |
| Exact Sciences Corporation | $34.40 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $28.14 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $23.84 | 2023 | Quviviq |
| Dexcom, INC. | $23.83 | 2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $22.18 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.70 | 2022 | |
| Vivus LLC | $20.60 | 2023 | Qsymia |
| Upsher-Smith Laboratories LLC | $18.65 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.12 | 2021 | |
| Currax Pharmaceuticals LLC | $15.42 | 2025 | Contrave |
| Ethicon US, LLC | $14.68 | 2022 | |
| Medtronic, INC. | $14.68 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ansa Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.